References for Chapter 20
Lipid-Lowering Drugs

William H. Frishman, MD
Wilbert S. Aronow, MD


87. Solano MP, Goldberg RB: Management of dyslipid-


170. Lipid Research Clinics Program: The Lipid Re-


194. Gordon DJ, Knoke J, Probstfield JL, et al, for the Lipid Research Clinics Program: High-density li-


243. Leiss O, Meyer-Krahmer K, Von Bergmann K: Bili-


302. Blais L, Desgagne A, LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors


358. The Lovastatin Pravastatin Study Group: A multi-


382. Langtry HD, Markham A: Fluvastatin: A review of
383. Davidson MH, FLUENT investigation group: Flu-
vatatin Long-Term Extension Trial (FLUENT): Sum-
cicacy with fluvastatin as monotherapy, and com-
bined with cholestyramine (a 156 week multicenter
and safety of a combination fluvastatin-bezafibrate
 treatment for familial hypercholesterolemia: Com-
parative analysis with a fluvastatin-cholestyramine
of restenosis after coronary balloon angioplasty:
Rationale and design of the Fluvastatin Angioplast-
y Restenosis (FLARE) trial. Am J Cardiol 73:5D,
1994.
fluvastatin on coronary atherosclerosis in patients
with mild to moderate cholesterol elevations [Li-
poprotein and Coronary Atherosclerosis Study
388. Liem A, van Boven AJ: Effects of fluvastatin ad-
ministered immediately after an acute MI on myo-
cardial ischemia. Presented at the American Heart
Association Scientific Sessions 2000, New Orleans,
vatatin lowers atherogenic dense low-density li-
poproteins in postmenopausal women with the
atherogenic lipoprotein phenotype. Circulation
ity, and pharmacokinetics of an extended-release
formulation of fluvastatin administered once daily
to patients with primary hypercholesterolemia. J
tion of LDL-cholesterol by 25% to 69% in patients
with primary hypercholesterolemia by atorvastatin:
A new HMG-CoA reductase inhibitor. Arterioscler
392. Bakker-Arkema RG, Davidson MH, Hgolstein RJ,
et al: Efficacy and safety of a new HMG-CoA reduc-
tase inhibitor, atorvastatin, in patients with hypertri-
393. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ:
Pharmacodynamic effects and pharmacokinetics
of atorvastatin after administration in normochole-
sterolemic subjects in the morning and evening. J
and efficacy of long-term statin treatment for car-
diovascular events in patients with coronary heart
disease and abnormal liver tests in the Greek Ator-
vastatin and Coronary Heart Disease Evaluation
(GREACE) study: a post-hoc analysis. Lancet 376:
Effect of aggressive versus conventional lipid low-
ering on atherosclerosis progression in familial
hypercholesterolaemia (ASAP): A prospective,
randomised, double-blind trial. Lancet 357:577,
395. Illingworth DR, Crouse J Jr, Hunninghake DB,
et al: A comparison of simvastatin and atorvastatin
up to maximal recommended doses in a large mul-
ticenter randomized clinical trial. Curr Med Res
396. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-
lowering therapy compared with angioplasty in
stable coronary artery disease. Atorvastatin versus
Revascularization Treatment investigators. N Engl J
397. Statins for high-risk patients without heart disease
398. Davidson MH: Rosuvastatin: A highly efficacious
statin for the treatment of dyslipidaemia. Expert
Opin Invest Drugs 11:125, 2002.
399. McTaggart F, Buckett L, Davidson R, et al: Pre-
clinical and clinical pharmacology of rosuvastatin,
a new 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitor. Am J Cardiol 87(Suppl):28B,
400. Olsson AG: Statin therapy and reductions in low-
density lipoprotein cholesterol: Initial clinical data
on the potent new statin rosuvastatin. Am J Cardiol
401. Jones PH, Davidson MH, Stein EA, et al. Com-
parison of the efficacy and safety of rosuvastatin
versus atorvastatin, simvastatin, and pravastatin
across doses (STELLAR trial). Am J Cardiol 2003;
92: 152-160.
402. Alsheikh-Ali AA, Ambrose MS, Kuvin JT; Karas RH:
The safety of rosuvastatin as used in common
clinical practice. A postmarketing analysis. Circu-
high-intensity statin therapy on regression of coro-
nary atherosclerosis. The ASTEROID trial. JAMA
2006; 295: 156-1565.
404. Nicholls SJ, Tuzcu EM, Sipahi I, et al: Statins, high-
density lipoprotein cholesterol, and regression of


423. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major non-cardiac vascular surgery. *Circulation* 107: 1848,


449. Altschul R, Hoffer A, Stephen JD: Influence of


476. Elam MB, Hunninghake DB, Davis KB, et al: Effect of niacin on lipid and lipoprotein levels and


500a. Saravanan P, Davidson NC, Schmidt EB, Calder


557. Goldberg AC, Ostlund RE, Bateman JH, et al: Effect of plant stanol tablets on low-density lipo-


586. Nissen SE, Tuzcu EM, Brewer HB, et al for the ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators: Effect of ACAT inhibi-


611. Manolio T. Novel risk markers and clinical prac-


651. Lewis B: Relation of high-density lipoproteins to coronary artery disease. Am J Cardiol 52:5B, 1983.


714. Peterson SJ, Frishman WH: Targeting heme oxygenase: therapeutic implications for diseases of the

